First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. - Wikidata - awgldk - TriplyDB

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

http://www.wikidata.org/entity/Q34149952

about

Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update Adenosine receptors as drug targets--what are the challenges?Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Critical appraisal of ticagrelor in the management of acute coronary syndrome Relating human genetic variation to variation in drug responses.Association of MicroRNAs and YRNAs With Platelet Function.Ticagrelor: from concept to clinical evaluation.Ticagrelor: a review of its use in the management of acute coronary syndromes.Genetic determinants of on-clopidogrel high platelet reactivity.The evolution of antiplatelet therapy in cardiovascular disease.A comprehensive comparative review of adenosine diphosphate receptor antagonists.Genetic determinants of response to cardiovascular drugs.Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.Clinical pharmacogenomics of warfarin and clopidogrel.Personalizing antiplatelet therapy with clopidogrel.Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.P2Y12 receptor: platelet thrombus formation and medical interventions.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Clinical impact of genetically determined platelet reactivity.Platelet function testing and tailored antiplatelet therapy.Antiplatelet therapy: new pharmacological agents and changing paradigms.Genetics of platelet inhibitor treatment Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.Pharmacogenomics of oral antiplatelet drugs.Significance of antiplatelet therapy in emergency myocardial infarction treatment.Ticagrelor: a review of its use in adults with acute coronary syndromes.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.

P2860

Q24631111-F6D9B999-373A-4F33-A88D-F2FEE875D94A Q26822796-323FFEF3-33D9-41FE-8EAA-8AFE5BF666C9 Q26823542-3C9225C9-7837-443E-96D9-1CA8B446C766 Q27006031-DE77A28B-7E82-464A-9D9F-244868D60D7B Q29346491-FEA5AF9C-06E7-4141-AE2D-64CD84CFDBF0 Q30359686-5C67651D-26A5-4BB1-806B-C2C2557A4CDA Q34576281-67AEDD3B-026B-497D-92F4-C5BF4D6EB8F1 Q34805121-2B62B9BB-6B16-4B62-A317-87765F558E9C Q35660767-38CC69C1-C772-4268-A0BA-0A86CB5E3B90 Q36252524-F714BD08-8520-4EDE-BE91-3D973DDB5148 Q37341170-FEC94B96-05CC-476C-8975-B51E62F8515E Q37841570-A136EDD6-74F6-4E0B-8E09-EE09B3A38FAE Q37875063-DEEC0067-38A8-4EB4-B2AF-D0650A2CCCC0 Q37882695-983324A8-34CD-4FD1-9FFE-BB3B18B8E181 Q37900470-02D7F8D4-D50D-4920-A1C3-4F1CC18704E7 Q37973114-553B4E6F-AD53-4D8A-855C-538CAD40B430 Q37989811-236094DE-C7BF-4371-9E12-D6B6A6D6D061 Q37990848-8CFCAC17-8DB3-4F89-BF7F-5D026E6FAE78 Q38001453-F2586C8E-DD9A-479D-BC7A-DD77F11D0195 Q38008466-4A70D2CC-95DA-422E-9891-4B86BC0177C5 Q38016848-8F237296-8646-40CD-B4BF-A28E2EA7AB44 Q38040698-B0C4F59F-3045-49E4-9D87-279D92AAE34F Q38048837-E3B612A2-60E2-4DE3-A746-DF061E330A79 Q38051192-2FECF896-ECAC-4689-AD6A-9FB2F8DF3CC9 Q38053481-4917027A-9A6F-4CE0-A63E-ED84648D3989 Q38059616-2BFCF9C1-B682-4C9F-B1F8-A836651A7979 Q38094681-C24D9590-5CB6-43DE-84E7-349B05DD91D1 Q38117743-8FC5608C-D205-45A6-A4BE-A0F4A7EE9660 Q38131848-A4EFCBA4-4CFE-4F25-9772-CB59DF2EC237 Q38148597-EAA79AEB-DFE4-4280-AC5F-394FD30A8072 Q38195628-094A6F4E-36C7-40E9-BB9B-32D44F9D0C75 Q38209661-1C77B490-170F-4AFB-83C3-3368750BF9BF Q38352069-A02EDC05-B99C-49C7-BCF5-C34DE29F3F8A Q38401281-34386F33-FB49-4DEB-B6E6-AABDF8C5AFF5 Q38444425-95056591-737D-429A-B25C-4F2D09F8C716 Q38660595-4B2C5722-FE18-4233-AA97-3CDC57AD5C93 Q38677500-EB51C855-3220-483E-8141-F71DE6B29FA9 Q38750444-88E90F2C-7D92-4B03-8D8E-DD8BFC36CCFA Q38958862-48733B74-0D40-4280-B4CF-440217E6781D Q38974884-C3266E55-E443-479F-93BF-41E4CAC2C184

P2860

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

http://www.wikidata.org/entity/Q34149952

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

First analysis of the relation ...... and RESPOND genotype studies.

@ast

First analysis of the relation ...... and RESPOND genotype studies.

@en

First analysis of the relation ...... and RESPOND genotype studies.

@nl

type

label

First analysis of the relation ...... and RESPOND genotype studies.

@ast

First analysis of the relation ...... and RESPOND genotype studies.

@en

First analysis of the relation ...... and RESPOND genotype studies.

@nl

prefLabel

First analysis of the relation ...... and RESPOND genotype studies.

@ast

First analysis of the relation ...... and RESPOND genotype studies.

@en

First analysis of the relation ...... and RESPOND genotype studies.

@nl

P1433

Q34149952-990136AA-7139-4C48-96FC-E40780394A81

P1476

Q34149952-65A560A2-DC79-4CEE-9898-3836CFF8D599

P2093

Q34149952-7B2D22AE-0D51-4D61-A8EA-D3712357A775

Q34149952-89C2314C-6CC7-496E-AC81-2BA4EE9A2AD0

Q34149952-8F74C49A-AFF2-484E-BB8B-039ECCBAABBB

Q34149952-9D6D738A-70D7-4270-894C-AFA142DCF4E3

Q34149952-BE9FECA3-22A7-4539-8B06-B641FAFECFC1

Q34149952-FF105B40-EFE1-49DC-8A1D-D987E77248EB

P304

Q34149952-ED83E752-48D4-44A3-810A-822155EFC35A

P31

Q34149952-CB8B8353-97CF-4714-A4BC-4C5248BD96C5

P356

Q34149952-61C5AF9F-936A-420B-B11A-2E30BFFA67FF

P433

Q34149952-690BAB77-9351-45FD-9570-BDAEECB0A473

P478

Q34149952-D399F680-428A-480D-8AA4-5627BFD419BA

P50

Q34149952-68A14E20-5DEE-4878-8E0A-FA621F7CCCDE

P577

Q34149952-E44DFB12-699A-4772-8F61-6682226444EF

P698

Q34149952-C6AF4CE4-2C49-482D-946E-3BEC0FBA5864

P921

Q34149952-CE3958EF-7705-432B-876D-E9A8CFA3E225

Q34149952-EC1D0B47-51F3-4E27-A254-93F3FC8869A9

P356

CIRCGENETICS.110.958561

P1433

Circulation: Cardiovascular Genetics

P1476

First analysis of the relation ...... T and RESPOND genotype studies

@en

P2093

Cheryl Wei

http://www.w3.org/2001/XMLSchema#string

Kathleen Butler

http://www.w3.org/2001/XMLSchema#string

Kevin P Bliden

http://www.w3.org/2001/XMLSchema#string

Martin Armstrong

http://www.w3.org/2001/XMLSchema#string

Paul A Gurbel

http://www.w3.org/2001/XMLSchema#string

Udaya S Tantry

http://www.w3.org/2001/XMLSchema#string

P304

556-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCGENETICS.110.958561

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Robert F. Storey

P577

2010-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21079055

http://www.w3.org/2001/XMLSchema#string

P921